RUSH University Medical Center and the RUSH Center for Congenital Structural Heart Disease have been at the forefront in developing state-of-the-art therapies for congenital and acquired structural disorders. Minimally invasive innovations, such as transaortic valve replacement (TAVR), MitraClip and the CoreValve, have helped patients enjoy faster recovery times, less pain and, typically, less cardiac rehabilitation.

Clifford Kavinsky, MD, PhD, joins the podcast to profile the next generation of minimally invasive cardiac care, including several clinical trials that RUSH is participating in. Dr. Kavinsky is the Director of the RUSH Center for Adult Structural Heart Disease, the Chief of the Section of Structural and Interventional Cardiology and the Associate Director for the Cardiovascular Disease Fellowship Program. He is an expert on catheter-based therapies for heart and vascular disease and is an internationally recognized leader in the use of novel treatments for adults with congenital and structural heart disease.

“It’s a really exciting time to practice cardiovascular medicine when there’s such an explosion of technology and thrust towards less invasive techniques that historically we’ve always done with large surgical procedures. It’s particularly satisfying to be able to put a new valve in a patient and send them home the next day.  When you think about surgery and how they used to be in the hospital for a week and recover for six to 12 weeks, it’s quite remarkable.”

CME link: https://cmetracker.net/RUSH/Publisher?page=pubOpen#/EventID/483920/